Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke.
Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke.
复制标题
亚甲蓝治疗可延缓永久性缺血性中风中灌注扩散失配至梗塞的进展。
DOI：
10.1016/j.brainres.2014.09.007
复制
发表时间：
2014-11-07
期刊：
影响因子：
2.9
通讯作者：
Duong TQ
中科院分区：
文献类型：
--
作者：
Rodriguez P;Jiang Z;Huang S;Shen Q;Duong TQ
中风是世界上发病率和死亡率的主要原因。低剂量亚甲蓝（MB）已安全用于治疗人类高铁血红蛋白血症和氰化物中毒，具有能量增强和抗氧化特性。我们检验了亚甲基蓝治疗延迟危险组织进展的假设。灌注-扩散不匹配）在两种MB治疗剂量下对大鼠永久性大脑中动脉闭塞中的梗死的影响。使用系列MRI评价MB治疗疗效。主要调查结果如下：（i）MB显著延长了灌注-扩散不匹配，（ii）MB轻度增加了低灌注组织中的CBF，（iii）MB未改变永久性缺血性卒中的最终梗死体积，（iv）研究的1和3 mg/kg剂量对不匹配进展无剂量依赖性影响。这种神经保护作用可能是持续的ATP产生和增加危险组织的CBF的结果。鉴于MB的优良安全性，这项工作有可能很容易导致临床中风试验。
Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.